The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

IntroductionI got to experience a VW Virtus 1.0 TSI AT Topline. While there is the official review and a few other ownership ...

BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b ...

"I would argue the folks closer to the operational side know better than we do, and I want to make sure that it's not all ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

CEBU-BASED fuel retailer Top Line Business Development Corp. (Topline) has secured approval from the Securities and Exchange Commission (SEC) for its planned initial public offering (IPO).  “Our ...

In its review, Topline Securities commented that the local bourse experienced a volatile session, attempting to recover from the previous day's sharp sell-off. The index initially showed strength and ...

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

These three small-cap stocks offer healthy long-term growth prospects, making them attractive buys. The post 3 Small Caps ...